This page translates the Chinese website. Product availability and approved uses vary by country. Packaging and linked prescribing information may be in Chinese.
There are currently no matching products in this field.
Geleli®
The First Adalimumab Biosimilar in China
adalimumab injection · Qletli®
Therapeutic Area
autoimmune disease
Markets
China, UK
Mechanism of action
Specifically binds to TNF-α and neutralizes its biological activity, blocking interaction with the cell-surface TNF-α receptors p55 and p75.
Source: August 2024 corporate brochure, p. 02. Dates follow the brochure’s approval/market-entry record; they do not imply identical brand names or indications across markets.
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name adalimumab injectionBrand Name Geleli® QLETLI®English name Adalimumab InjectionChinese Pinyin Adamu Dankang Zhusheye
Ingredients
The principal ingredient is adalimumab.
Specifications
20 mg/0.4 mL; one prefilled syringe per carton; subcutaneous injection
Description
This product is a clear liquid prefilled in a syringe
Indications
Crohn's disease in children
plaque psoriasis in children
polyarticular juvenile idiopathic arthritis
Chinese Approval No.
Chinese Approval No. S20217001
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name adalimumab injectionBrand Name Geleli® QLETLI®English name Adalimumab InjectionChinese Pinyin Adamu Dankang Zhusheye
Ingredients
The principal ingredient is adalimumab.
Specifications
40 mg/0.8 mL; one prefilled syringe per carton; subcutaneous injection
Description
This product is a clear liquid prefilled in a syringe
Indications
rheumatoid arthritis
ankylosing spondylitis
psoriasis
Crohn's disease
uveitis
Crohn's disease in children
plaque psoriasis in children
polyarticular juvenile idiopathic arthritis
Chinese Approval No.
Chinese Approval No. S20190038
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
Pubeixi®
bevacizumab injection · Avzivi® / Bevyx®
Therapeutic Area
tumor targeted therapy
Markets
China, United States, European Union, Brazil
Mechanism of action
Binds to human vascular endothelial growth factor (VEGF), inhibiting its interaction with its receptors and blocking angiogenesis signaling.
Source: August 2024 corporate brochure, p. 03. Dates follow the brochure’s approval/market-entry record; they do not imply identical brand names or indications across markets.
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
Drug name
Generic Name bevacizumab injectionBrand Name Pubeixi® POBEVCY®English name Bevacizumab InjectionChinese Pinyin Beifazhu Dankang Zhusheye
Ingredients
The principal ingredient is bevacizumab.
Specifications
100 mg/4 mL; one vial per carton; intravenous injection
Description
This product is a sterile solution for intravenous injection, pH 5.9-6.3, clear to slightly opalescent, colorless to light brown liquid
Indications
metastatic colorectal cancer
Advanced, metastatic or recurrent non-small cell lung cancer
cervical cancer
recurrent glioblastoma
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
Chinese Approval No.
Chinese Approval No. S20210044
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with relevant treatment experience according to the instructions and prescriptions.
Drug name
Generic Name bevacizumab injectionBrand Name Pubeixi® POBEVCY®English name Bevacizumab InjectionChinese Pinyin Beifazhu Dankang Zhusheye
Ingredients
The principal ingredient is bevacizumab.
Specifications
400 mg/16 mL; one vial per carton; intravenous injection
Description
This product is a sterile solution for intravenous injection, pH 5.9-6.3, clear to slightly opalescent, colorless to light brown liquid
Indications
metastatic colorectal cancer
Advanced, metastatic or recurrent non-small cell lung cancer
cervical cancer
recurrent glioblastoma
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
Chinese Approval No.
Chinese Approval No. S20210045
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
Shiruili®
The World’s First Tocilizumab Biosimilar
tocilizumab injection · TOFIDENCE®
Therapeutic Area
autoimmune disease
Markets
China, United States, European Union, Switzerland, United Kingdom
Mechanism of action
Targets the interleukin-6 receptor (IL-6R), specifically binding to soluble and membrane-bound receptors (sIL-6R and mIL-6R) and inhibiting the signaling they mediate.
Source: August 2024 corporate brochure, p. 04. Dates follow the brochure’s approval/market-entry record; they do not imply identical brand names or indications across markets.
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
Drug name
Generic Name tocilizumab injectionBrand Name Shiruili® TOFIDENCE®English name Tocilizumab InjectionChinese Pinyin Tuozhu Dankang Zhusheye
Ingredients
The principal ingredient is tocilizumab.
Specifications
80 mg/4 mL; 1 or 4 vials per carton; intravenous infusion
Description
This product is colorless to light yellow clear liquid with slight opalescence.
Indications
rheumatoid arthritis
systemic juvenile idiopathic arthritis
cytokine release syndrome
Chinese Approval No.
Chinese Approval No. S20230003
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-9998703
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
Drug name
Generic Name tocilizumab injectionBrand Name Shiruili® TOFIDENCE®English name Tocilizumab InjectionChinese Pinyin Tuozhu Dankang Zhusheye
Ingredients
The principal ingredient is tocilizumab.
Specifications
200 mg/10 mL; 1 or 4 vials per carton; intravenous infusion
Description
This product is colorless to light yellow clear liquid with slight opalescence.
Indications
rheumatoid arthritis
systemic juvenile idiopathic arthritis
cytokine release syndrome
Chinese Approval No.
Chinese Approval No. S20240009
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-9998703
Disclaimer: The following products are prescription drugs and must be used under the guidance of medical and pharmaceutical professionals with reference to the instructions and prescriptions.
Drug name
Generic Name tocilizumab injectionBrand Name Shiruili® TOFIDENCE®English name Tocilizumab InjectionChinese Pinyin Tuozhu Dankang Zhusheye
Ingredients
The principal ingredient is tocilizumab.
Specifications
400 mg/20 mL; 1 or 4 vials per carton; intravenous infusion
Description
This product is colorless to light yellow clear liquid with slight opalescence.
Indications
rheumatoid arthritis
systemic juvenile idiopathic arthritis
cytokine release syndrome
Chinese Approval No.
Chinese Approval No. S20230001
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:400-9998703
Beitaning®
China Class 1 Innovative Drug
bevifibatide citrate injection
Therapeutic Area
cardiovascular disease
Markets
China
Mechanism of action
A peptide β3 integrin receptor inhibitor that targets both the platelet glycoprotein receptor αIIbβ3 (also known as IIb/IIIa) and the integrin receptor αvβ3.
Source: August 2024 corporate brochure, p. 05. Dates follow the brochure’s approval/market-entry record; they do not imply identical brand names or indications across markets.
Disclaimer: The following products are all prescription drugs and must be used under the guidance of a physician with experience in treating cardiovascular disease according to the instructions.
Drug name
Generic Name bevifibatide citrate injectionBrand Name Beitaning® BETAGRIN®English name Bevifibatide Citrate InjectionChinese Pinyin Juyuansuan Beiweibatai Zhusheye
Ingredients
The principal active ingredient is bevifibatide citrate.
Specifications
20 mg/10 mL, intravenously
Description
This product is colorless clear liquid
Indications
For use in patients with acute coronary syndrome undergoing percutaneous coronary intervention, including intracoronary stent placement, to reduce the risk of acute occlusion, stent thrombosis, no-reflow, and slow flow
Chinese Approval No.
Chinese Approval No. H20240030
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
Aishali® / Xishali®
ustekinumab injection · STARJEMZA® / Usymro®
Therapeutic Area
autoimmune disease
Markets
China, United States, European Union, United Kingdom
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name ustekinumab injectionBrand Name Aishali®English name Ustekinumab InjectionChinese Pinyin Wusinu Dankang Zhusheye
Ingredients
The principal ingredient is ustekinumab.
Specifications
45 mg/0.5 mL; one prefilled syringe per carton; subcutaneous injection
Description
This product is a colorless to light yellow clear solution prefilled in a syringe
Indications
Adult plaque psoriasis
Crohn's disease
plaque psoriasis in children
Chinese Approval No.
Chinese Approval No. CXSS2400048
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name ustekinumab injectionBrand Name Aishali®English name Ustekinumab InjectionChinese Pinyin Wusinu Dankang Zhusheye
Ingredients
The principal ingredient is ustekinumab.
Specifications
90 mg/mL; one prefilled syringe per carton; subcutaneous injection
Description
This product is a colorless to light yellow clear solution prefilled in a syringe
Indications
Adult plaque psoriasis
Crohn's disease
plaque psoriasis in children
Chinese Approval No.
Chinese Approval No. CXSS2400046
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name ustekinumab injectionBrand Name Xishali®English name Ustekinumab Injection (Intravenous Infusion)Chinese Pinyin Wusinu Dankang Zhusheye
Ingredients
The principal ingredient is ustekinumab.
Specifications
130 mg/26 mL; one vial per carton; intravenous infusion
Description
This product is a sterile solution for intravenous infusion
Indications
Crohn's disease
Chinese Approval No.
Chinese Approval No. CXSS2400047
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
golimumab
Approved in Europe and the United States · Not yet approved in China
golimumab injection · Gotenfia® / IMMGOLIS™
Therapeutic Area
autoimmune disease
Markets
European Union, United States (not yet approved in China)
Specifications and packaging
golimumab injection (50 mg/0.5 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name golimumab injectionBrand Name Gotenfia® / IMMGOLIS™English name Golimumab InjectionChinese Pinyin Gelimu Dankang Zhusheye
Ingredients
The principal ingredient is golimumab.
Specifications
50 mg/0.5 mL/tube/box, subcutaneous injection
Description
This product is a colorless to light yellow clear solution prefilled in a syringe
Indications
rheumatoid arthritis
ulcerative colitis
Chinese Approval No.
It has been approved for marketing in Europe and the United States, but has not yet been approved for marketing in China.
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
golimumab injection (100 mg/mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name golimumab injectionBrand Name Gotenfia® / IMMGOLIS™English name Golimumab InjectionChinese Pinyin Gelimu Dankang Zhusheye
Ingredients
The principal ingredient is golimumab.
Specifications
100 mg/mL/tube/box, subcutaneous injection
Description
This product is a colorless to light yellow clear solution prefilled in a syringe
Indications
rheumatoid arthritis
ulcerative colitis
Chinese Approval No.
It has been approved for marketing in Europe and the United States, but has not yet been approved for marketing in China.
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
golimumab injection (50 mg/4 mL)
Disclaimer: The following products are prescription drugs and must be used under the guidance of a physician with experience in treating autoimmune diseases according to the instructions.
Drug name
Generic Name golimumab injectionBrand Name Gotenfia® / IMMGOLIS™English name Golimumab InjectionChinese Pinyin Gelimu Dankang Zhusheye
Ingredients
The principal ingredient is golimumab.
Specifications
50 mg/4 mL/bottle/box, intravenous infusion
Description
This product is a sterile solution for intravenous infusion
Indications
rheumatoid arthritis
Chinese Approval No.
It has been approved for marketing in Europe and the United States, but has not yet been approved for marketing in China.
Refer to the prescribing information for dosage and administration, adverse reactions, contraindications, precautions and other details. Medical consultation hotline:4009998703
More candidate drugs under development can be found in the R&D pipeline; for business cooperation and supply, please contact the business team.
